Stock IVACC INTERVACC AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Intervacc AB

Equities

IVACC

SE0009607252

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
3.18 SEK -2.45% Intraday chart for Intervacc AB +0.63% -49.76%
05-15 Intervacc AB Announces Board Appointments CI
05-15 Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
INTERVACC AB Stock Intervacc AB
-49.76% 23.47M
D
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 116B
B+
ARGENX SE Stock argenx SE
+22.18% 27.03B
B
BIONTECH SE Stock BioNTech SE
-21.81% 20.36B
B+
GENMAB A/S Stock Genmab A/S
-16.89% 16.43B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.91B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.94B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.59B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IVACC Stock
  4. Ratings Intervacc AB